

08-25-2000



101432491

T

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark OfficeAttorney Docket No.
2263

To the Honorable Commission

original documents or copy thereof.

1. Name of conveying party(ies):

The Female Health Company

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

2. Name and address of receiving party(ies)

Name: Gary Benson, Robert Johander, Daniel Bishop, Mike Snow and W.G. Securities Limited

Internal Addresses:

Gary Benson, 2925 Dean Parkway, Minneapolis, MN 55416
Robert Johander, 8480 Montgomery Ct., Eden Prairie, MN 55347
Daniel Bishop, 17235 2 Mile Rd., Franksville, WI 53126
Mike Snow, 90 South 7th Street, Minneapolis, MN 55402
W.G. Securities Limited, 774 Mays Blvd., #10, Incline Village, NV 89451

Street Addresses

Gary Benson, 2925 Dean Parkway, Minneapolis, MN 55416
Robert Johander, 8480 Montgomery Ct., Eden Prairie, MN 55347
Daniel Bishop, 17235 2 Mile Rd., Franksville, WI 53126
Mike Snow, 90 South 7th Street, Minneapolis, MN 55402
W.G. Securities Limited, 774 Mays Blvd., #10, Incline Village, NV 89451Additional name(s) & address(es) attached? ☐ Yes ☒ No

3. Nature of conveyance:

☐ Assignment☐ Merger☒ Security Agreement☐ Change of Name☐ OtherExecution Date: August 16, 2000

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is: _____

A. Patent Application No.(s):

B. Patent No.(s)

4,735,621, 4,834,113, 4,976,273, 5,094,250, 5,146,930,
5,168,881, 5,193,555, 5,490,519, 5,490,525, 5,603,802,
5,622,185, 5,623,946, 5,695,585Additional Numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Leslie S. Miller, Esq.Internal Address: Reinhart, Boerner, Van Deuren,Norris & Rieselbach, s.c.1000 North Water Street, Suite 2100Milwaukee, WI 53202-3186Street Address: Reinhart, Boerner, Van Deuren,
Norris & Rieselbach, s.c.
1000 North Water Street, Suite 2100
City: Milwaukee State: WI ZIP: 53202-3186

6. Total number of applications and patents involved: [13]

7. Total fee (37 CFR 3.41)\$520.00

☒ Enclosed☐ Authorized to be charged to deposit account☒ Any deficiencies in enclosed fee should be charged to Deposit Account.

8. Deposit account number:

18-0882

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

*To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document*Leslie S. Miller

Name of Person Signing

Signature

August 23, 2000

Date

Total number of pages including cover sheet, attachments, and document: [16]

Mail documents to be recorded with required cover sheet information to:

Commissioner of Patents & Trademarks, Box Assignments
Washington, D.C. 20231

COLLATERAL ASSIGNMENT, PATENT MORTGAGE, AND SECURITY AGREEMENT

THIS COLLATERAL ASSIGNMENT, PATENT MORTGAGE AND SECURITY AGREEMENT ("Assignment") is made as of this 16th day of August, 2000, by and among THE FEMALE HEALTH COMPANY, a Wisconsin corporation and THE FEMALE HEALTH COMPANY (UK) PLC. (jointly referred to as "Assignor"); and Gary Benson, Robert Johander, Daniel Bishop, Mike Snow, and W.G. Securities Limited Partnership (jointly referred to as "Assignee").

RECITALS

A. Assignee has agreed to lend to Assignor certain funds (the "Loan"), and Assignor desires to borrow such funds from Assignee. The Loan will be evidenced by one or more promissory notes or other evidences of credit extensions (a "Note" or, collectively, the "Notes") and will be secured in part pursuant to the terms of certain loan documents, including a security agreement, of even date herewith (the "Loan Documents").

B. In order to induce Assignee to make the Loan, Assignor has agreed to assign certain intangible property to Assignee for purposes of securing the obligations of Assignor to Assignee.

NOW, THEREFORE, THE PARTIES HERETO AGREE AS FOLLOWS:

1. Assignment, Patent Mortgage, and Grant of Security Interest. As collateral security for the prompt and complete payment and performance of all of Assignor's present or future indebtedness, obligations and liabilities of every kind and character ("Obligations"), owed to Assignee, including without limitation the Loan, Assignor hereby assigns, transfers, conveys and grants a security interest and mortgage to Assignee, as security, Assignor's entire right, title and interest in, to and under the following (all of which shall collectively be called the "Collateral"):

(a) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit A attached hereto (collectively, the "Patents");

(b) Any trademark and service mark rights, whether registered or not, applications to register and registrations of the same and like protections, all trade names, trade styles, designs, and the like, all elements of package or trade dress of goods, and the entire goodwill of the business of Assignor connected with and

symbolized by such trademarks, including without limitation those set forth on Exhibit B attached hereto (collectively, the "Trademarks");

- (c) Any and all claims for damages by way of past, present and future infringement of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;
- (d) All licenses or other rights to use any of the Patents or Trademarks, and all license fees and royalties arising from such use;
- (e) All amendments, extensions, renewals and extensions of any of the Patents or Trademarks; and
- (f) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

THE INTEREST IN THE COLLATERAL BEING ASSIGNED HEREUNDER SHALL NOT BE CONSTRUED AS A CURRENT ASSIGNMENT, BUT AS A CONTINGENT ASSIGNMENT TO SECURE ASSIGNOR'S OBLIGATIONS TO ASSIGNEE.

2. Authorization and Request. Assignor authorizes and requests that the Commissioner of Patents and Trademarks and corresponding officials in other countries of the world as pertinent record this conditional assignment.

3. Covenants and Warranties. Assignor represents, warrants, covenants and agrees as follows:

- (a) Assignor is the sole and lawful owner of the Collateral, except for non-exclusive licenses granted by Assignor to its customers in the ordinary course of business and except for liens, encumbrances or security interests to which Assignee has consented in writing.
- (b) Performance of this Assignment does not conflict with or result in a breach of any agreement to which Assignor is party or by which Assignor is bound.
- (c) During the term of this Assignment, Assignor will not transfer or otherwise encumber any interest in the Collateral, except for non-exclusive licenses granted by Assignor in the ordinary course of business.
- (d) Each of the Patents is valid and enforceable, and no part of the Collateral has been judged invalid or unenforceable, in whole or in part, and no claim has been made that any part of the Collateral violates the rights of any third party.

- (e) Assignor shall promptly advise Assignee of any material change in the composition of the Collateral, including but not limited to any subsequent ownership right of the Assignor in or to any Patent or Trademark not specified in this Assignment.
- (f) Assignor shall at its expense:
- (i) protect, defend and maintain the validity and enforceability of the Patents and Trademarks;
 - (ii) use its best efforts to detect infringements of the Patents and Trademarks and promptly advise Assignee in writing of material infringements detected; and
 - (iii) not allow any Patents or Trademarks to be abandoned, forfeited or dedicated to the public without the written consent of Assignee, which shall not be unreasonably withheld.
- (g) Assignor shall, from time to time, execute and file such other instruments, and take such further actions as Assignee may request from time to time to perfect or continue the perfection of Assignee's interest in the Collateral to perfect or continue the perfection of Assignee's interests in the Collateral, at Assignor's sole expense.
- (h) This Assignment creates, and in the case of after acquired Collateral, this Assignment will create at the time Assignor first has rights in such after acquired Collateral, in favor of Assignee a valid and perfected first priority security interest in the Collateral in the United States securing the payment and performance of the Obligations owed to Assignee upon making the filings referred to in clause (i) below.
- (i) Except for, and upon, the filing of a UCC-1 financing statement with the Illinois Secretary of State, and the filing with the United States Patent and Trademark office with respect to the Patents and Trademarks necessary to perfect the security interests and assignment created hereunder, and, except as has been already made or obtained, no authorization, approval or other action by, and no notice to or filing with, any governmental authority or regulatory body is required either:
- (i) for the grant by Assignor of the security interest granted hereby or for the execution, delivery or performance of this Assignment by Assignor; or
 - (ii) for the perfection in the United States or the exercise by Assignee of its rights and remedies hereunder.

(j) All information heretofore, herein or hereafter supplied to Assignee by or on behalf of Assignor with respect to the Collateral is accurate and complete in all material respects.

(k) Assignor shall not enter into any agreement that would materially impair or conflict with Assignor's obligations hereunder without Assignee's prior written consent. Assignor shall not permit the inclusion in any contract to which it becomes a party of any provisions that could or might in any way impair or prevent the creation of a security interest in Assignor's rights and interests in any property included within the definition of the Collateral acquired under such contracts.

(l) Upon any officer or member of Assignor obtaining knowledge thereof, Assignor will promptly notify Assignee in writing of any event that materially adversely affects the value of any of the Collateral, the ability of Assignor or Assignee to dispose of any of the Collateral or the rights and remedies of Assignee in relation thereto, including the levy of any legal process against any of the Collateral.

4. Assignee's Rights. Assignee shall have the right, but not the obligation, to take, at Assignor's sole expense, any actions that Assignor is required under this Assignment to take but which Assignor fails to take. Assignor shall reimburse and indemnify Assignee for all costs and expenses incurred in the reasonable exercise of its rights under this Section 4.

5. Inspection Rights. Assignor hereby grants to Assignee and its employees, representatives and agents the right to visit, during reasonable hours upon prior reasonable notice to Assignor, and any of Assignor's and its subcontractors' plants and facilities that manufacture, install or store products (or that have done so during the prior six-month period) that are sold under any of the Collateral, and to inspect the products and quality control records relating thereto upon reasonable notice to Assignor and as often as may be reasonably requested; provided, however, nothing herein shall entitle Assignee access to Assignor's trade secrets and other proprietary information.

6. Further Assurances; Attorney in Fact.

(a) On a continuing basis, Assignor will, subject to any prior licenses, encumbrances and restrictions and prospective licenses, make, execute, acknowledge and deliver, and file and record in the proper filing and recording places in the United States, all such instruments, including appropriate financing and continuation statements and collateral agreements and filings with the United States Patent and Trademark Office, and take all such action as may reasonably be deemed necessary or advisable, or as requested by Assignee, to perfect Assignee's security interest in all Patents and Trademarks and otherwise to carry out the intent

and purposes of this Collateral Assignment, or for assuring and confirming to Assignee the grant or perfection of a security interest in all Collateral.

(b) Assignor hereby irrevocably appoints Assignee as Assignor's attorney-in-fact, with full authority in the place and stead of Assignor and in the name of Assignor, Assignee or otherwise, from time to time in Assignee's discretion, to take any action and to execute any instrument which Assignee may deem necessary or advisable to accomplish the purposes of this Collateral Assignment, including:

(i) To modify, in its sole discretion, this Collateral Assignment without first obtaining Assignor's approval of or signature to such modification by amending Exhibit A and Exhibit B, thereof, as appropriate, to include reference to any right, title or interest in any Patents or Trademarks acquired by Assignor after the execution hereof or to delete any reference to any right, title or interest in any Patents or Trademarks in which Assignor no longer has or claims any right, title or interest; and

(ii) To file, in its sole discretion, one or more financing or continuation statements and amendments thereto, relative to any of the Collateral without the signature of Assignor where permitted by law; and

(iii) Upon an Event of Default hereunder, and following the exercise of any of the remedies provided hereby, to assign and transfer title to the Collateral to its own (or its nominee's) name or to the name of any purchaser of any of the Collateral at a public or private foreclosure sale. Assignor covenants and agrees to cooperate with Assignee to the extent necessary to permit Assignee to exercise its remedies following an Event of Default by Assignor hereunder.

7. Events of Default. The occurrence of any of the following shall constitute an Event of Default under the Assignment:

(a) An Event of Default occurs under the Loan Documents or any Note;

(b) Assignor breaches any warranty or agreement made by Assignor in this Assignment; or

(c) Assignor breaches any of the terms or conditions of any Obligations owed to Assignee.

8. Remedies. Upon the occurrence of an Event of Default, Assignee shall have the right:

- (a) to declare the entire amount of the Loan, or any other Obligation owed to Assignee, immediately due and payable;
- (b) to exercise any rights and remedies Assignee may have under the Loan Documents, other documents regarding any of the Obligations or applicable law; and
- (c) to exercise all the remedies of a secured party under the Illinois Uniform Commercial Code, including without limitation the right to require Assignor to assemble the Collateral and any tangible property in which Assignee has a security interest and to make it available to Assignee at a place designated by Assignee. Assignee shall have a nonexclusive, royalty free license to use the Patents and Trademarks to the extent reasonably necessary to permit Assignee to exercise its rights and remedies upon the occurrence of an Event of Default. Assignor will pay any expenses (including attorneys' fees) incurred by Assignee in connection with the exercise of any of Assignee's rights hereunder, including without limitation any expense incurred in disposing of the Collateral. All of Assignee's rights and remedies with respect to the Collateral shall be cumulative.

9. Indemnity. Assignor agrees to defend, indemnify and hold harmless Assignee and its officers, employees, and agents against:

- (a) all obligations, demands, claims, and liabilities claimed or asserted by any other party in connection with the transactions contemplated by this Agreement; and
- (b) all losses or expenses in any way suffered, incurred, or paid by Assignee as a result of or in any way arising out of, following or consequential to transactions between Assignee and Assignor, whether under this Assignment or otherwise (including without limitation attorneys fees and expenses), except for losses arising from or out of Assignee's gross negligence or willful misconduct.

10. Reassignment. At such time as Assignor shall completely satisfy all of the Obligations secured hereunder, Assignee shall execute and deliver to Assignor all deeds, assignments and other instruments as may be necessary or proper to revest in Assignor full title to the property assigned hereunder, subject to any disposition thereof which may have been made by Assignee pursuant hereto.

11. Course of Dealing. No course of dealing, nor any failure to exercise, nor any delay in exercising any right, power or privilege hereunder shall operate as a waiver thereof.

12. Attorneys Fees. If any action relating to this Assignment is brought by either party hereto against the other party, the prevailing party shall be entitled to recover reasonable attorneys fees, costs and disbursements.


13. Amendments. This Assignment may be amended only by a written instrument signed by both parties hereto.

14. Counterparts. This Assignment may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute the same instrument.

15. Wisconsin Law. This Assignment shall be governed by the laws of the State of Wisconsin, without regard for its choice of law provisions.

IN WITNESS WHEREOF, the parties have executed this Assignment on the day and year first above written.


**THE FEMALE HEALTH
COMPANY**

By: 
O.B. Parrish

Title: Chairman

Date: 3/16/00

**THE FEMALE HEALTH
COMPANY (UK) PLC.**

By: 
O.B. Parrish

Title: Chairman

Date: 3/16/00

EXHIBIT A

Patents

Issued U.S. Patents

<u>Patent No.</u>	<u>Issue Date</u>	<u>Title</u>
4,735,621	April 5, 1988	Tubular Protective Device for Protection Against Transfer of Infectious Matter During Sexual Intercourse
4,834,113	May 30, 1989	Prophylactic Device
4,976,273	December 11, 1990	Tubular Protective Device for Protection Against Transfer of Infectious Matter During Sexual Intercourse
5,094,250	March 10, 1992	Tubular Protective Device for Protection Against Transfer of Infectious Matter During Sexual Intercourse
5,146,930	September 15, 1992	Contraceptive and Anti-Infective Barrier Device
5,168,881	December 8, 1992	Prophylactic Device
5,193,555	April 22, 1997	Barrier Device
5,490,519	February 13, 1996	Tubular Protective Device for Protection Against Transfer of Infectious Matter During Sexual Intercourse
5,490,525	February 13, 1996	Prophylactic Device
5,603,802	February 18, 1997	Method and Apparatus for Welding Bags to Rings
5,622,185	March 16, 1993	Barrier Device
5,623,946	April 29, 1997	Tubular Protective Device for Protection Against Transfer of Infectious Matter During Sexual Intercourse
5,695,585	December 9, 1997	Method and Apparatus for Welding Bags to Rings

Pending U.S. Patent Applications

<u>Serial No.</u>	<u>Filing Date</u>	<u>Title</u>
-------------------	--------------------	--------------

None

Issued Foreign Patents

<u>Country</u>	<u>Patent No.</u>	<u>Issue Date</u>	<u>Title</u>
Australia	623073	February 8, 1988	Tubular Protective Device for Protection Against Transfer of Infectious Matter During Sexual Intercourse
Australia	617,659	April 13, 1992	Contraceptive and Anti-Infective Barrier Device
Brazil	PI 8807397-1	March 26, 1996	Tubular Protective Device for Protection Against Transfer of Infectious Matter During Sexual Intercourse
Canada	1334270	February 7, 1995	Tubular Protective Device for Protection against Transfer of Infectious matter during Sexual Intercourse
Canada	1321936	September 7, 1993	Prophylactic Device
China P.R.	88101126	December 3, 1995	Tubular Protective Device for Protection Against Transfer of Infectious Matter During Sexual Intercourse
EPC	0280943	May 12, 1993	Tubular Protective Device for Protection Against Transfer of Infectious Matter During Sexual Intercourse
EPC	0581551	July 26, 1993	Method and Apparatus for Testing Bag-Like Means
EPC	0583893	May 28, 1997	Method and Apparatus for Forming Bags

<u>Country</u>	<u>Patent No.</u>	<u>Issue Date</u>	<u>Title</u>
EPC	0621126	January 28, 1998	Method and Apparatus for Forming Bags
EPC	0552814	May 27, 1998	Prophylactic Device
France	EPO 344179	August 26, 1992	Contraceptive and Anti-Infective Barrier Device
France	0280943	May 12, 1993	Tubular Protective Device for Protection Against Transfer of Infectious Matter During Sexual Intercourse
France	0552814	May 27, 1998	Prophylactic Device
Germany	P3874128.8	August 26, 1992	Contraceptive and Anti-Infective Barrier Device
Germany	3880859	May 12, 1993	Tubular Protective Device for Protection Against Transfer of Infectious Matter During Sexual Intercourse
Germany	DE3856196T2	May 27, 1998	Prophylactic Device
Great Britain	EPO 344179	August 26, 1992	Contraceptive and Anti-Infective Barrier Device
Great Britain	EPO 0280943	May 12, 1993	Tubular Protective Device for Protection Against Transfer of Infectious Matter During Sexual Intercourse
Great Britain	0552814	May 27, 1998	Prophylactic Device
Hong Kong	1386/1993	May 12, 1993	Tubular Protective Device for Protection Against Transfer of Infectious Matter During Sexual Intercourse
Italy	EPO 344179	August 26, 1992	Contraceptive and Anti-Infective Barrier Device

<u>Country</u>	<u>Patent No.</u>	<u>Issue Date</u>	<u>Title</u>
Italy	0280943	May 12, 1993	Tubular Protective Device for Protection Against Transfer of Infectious Matter During Sexual Intercourse
Italy	0552814	May 27, 1998	Prophylactic Device
Ireland	E78657	July 26, 1993	Method and Apparatus for Forming Bags
Japan	1913813	March 23, 1995	Tubular Protective Device for Protection Against Transfer of Infectious Matter During Sexual Intercourse
Japan	2754026	March 6, 1998	Prophylactic Device
New Zealand	223295	January 26, 1988	Tubular Protective Device for Protection Against Transfer of Infectious Matter During Sexual Intercourse
Singapore	9391205-3	February 28, 1994	Tubular Protective Device for Protection Against Transfer of Infectious Matter During Sexual Intercourse
South Korea	056589	November 19, 1992	Tubular Protective Device for Protection Against Transfer of Infectious Matter During Sexual Intercourse
Spain	0280943	May 12, 1993	Tubular Protective Device for Protection Against Transfer of Infectious Matter During Sexual Intercourse

Pending Foreign Patent Applications

<u>Country</u>	<u>App. No.</u>	<u>Filing Date</u>	<u>Title</u>
Japan	63501153	January 22, 1988	Contraceptive and Anti-Infective Barrier Device

<u>Country</u>	<u>App. No.</u>	<u>Filing Date</u>	<u>Title</u>
Japan	205754/1993	July 28, 1993	Method and Apparatus for Testing Bag-Like Means
Japan	205755/1993	July 28, 1993	Method and Apparatus for Forming Bags
Japan	205756/1993	July 28, 1993	Apparatus for and a Method of Welding a Reinforcing Member to a Bag Like Member

EXHIBIT B

Trademarks

Registered U.S. Trademarks

<u>Registration No.</u>	<u>Date Registered</u>	<u>Mark</u>
1,914,466	August 29, 1995	FEMIDOM
2,051,759	April 15, 1997	FEMALE SYMBOL DESIGN

U.S. Trademark Application

<u>Application No.</u>	<u>Application Date</u>	<u>Mark</u>
76/040,657	May 4, 2000	FC FEMALE CONDOM

Registered Foreign Trademarks

<u>Country</u>	<u>Registration No.</u>	<u>Date Registered</u>	<u>Mark</u>
Argentina	1494223	December 30, 1993	FEMY
Australia	A568219	November 27, 1998	FEMY
Benelux	478117	April 20, 1990	FEMIDOM
Benelux	492880	February 22, 1991	FEMIDOM
Canada	436983	December 9, 1994	REALITY
Canada	445902	August 11, 1995	REALITY & DESIGN
China	568928	October 20, 1991	FEMIDOM
Denmark	6637/89	November 10, 1989	FEMIDOM (Cl. 10)
Denmark	1992 01432	March 13, 1992	FEMIDOM (Cl. 5)
France	1588199	April 25, 1990	FEMIDOM (Cl. 5)
France	1700830	March 4, 1991	FEMIDOM (Cl. 5&10)
France	1483222	April 28, 1998	FEMIDOM (Cl. 10)

<u>Country</u>	<u>Registration No.</u>	<u>Date Registered</u>	<u>Mark</u>
Germany	1189128	November 22, 1993	FEMIDOM
Great Britain	1421515	April 11, 1990	FEMIDOM
Great Britain	1439834	September 12, 1990	FEMIDOM THE FEMALE CONDOM
Great Britain	1440030	September 12, 1990	FEMIDOM (Stylized)
Great Britain	1440031	September 12, 1997	FEMIDOM
Great Britain	1343074	November 5, 1994	FEMIDOM (Cl. 10)
India	528218	April 19, 1990	FEMIDOM (Cl. 10)
Ireland	136602	April 18, 1997	FEMIDOM (Cl. 5)
Ireland	136603	April 18, 1997	FEMIDOM (Cl. 10)
Japan	2503066	February 26, 1993	FEMIDOM (Cl. 5)
Japan	2571790	August 31, 1993	SERIES DEVICE (Cl. 10)
Japan	2598876	November 30, 1993	FAYDOME
Japan	2654107	April 28, 1994	SERIES DEVICE
Japan	2660071	May 31, 1994	Stylized "F"
Japan	4197785	October 9, 1998	FEMIDOM (Cl. 10)
Japan	4299828	July 30, 1999	Japanese Letters
Mexico	395640	August 13, 1990	FEMIDOM (Cl. 5)
Mexico	411087	December 13, 1991	FEMY
Mexico	447017	September 8, 1993	FEMY
Mexico	385419	August 13, 1995	FEMIDOM (Cl. 10)
New Zealand	201292	April 19, 1990	FEMIDOM
New Zealand	201291	April 19, 1997	FEMIDOM

<u>Country</u>	<u>Registration No.</u>	<u>Date Registered</u>	<u>Mark</u>
Norway	155556	March 11, 1993	FEMIDOM
S. Africa	90/2911	April 18, 1990	FEMIDOM (Cl. 5)
S. Africa	90/2912	April 18, 1990	FEMIDOM (Cl. 10)
South Korea	216959	July 18, 1990	FEMIDOM (Cl. 11&10)
South Korea	218119	August 2, 1991	FEMIDOM (Cl. 10&5)
Spain	1622526	March 8, 1991	FEMY (Cl. 5)
Spain	1622527	March 8, 1991	FEMY (Cl. 10)
Sweden	215102	November 24, 1989	FEMIDOM (Cl. 10)
Sweden	230104	February 7, 1992	FEMIDOM
Switzerland	380494	March 5, 1990	FEMIDOM
Switzerland	387924	February 25, 1991	FEMIDOM
Thailand	149367	August 23, 1990	FEMIDOM (Cl. 11)
Thailand	152019	August 23, 1990	FEMIDOM (Cl. 10)
Zambia	367/92	November 18, 1992	FEMIDOM
Zimbabwe	1109-92	November 18, 1992	FEMIDOM

Unregistered Foreign Trademarks

<u>Country</u>	<u>Application No.</u>	<u>Application Date</u>	<u>Mark</u>
India	528219	April 19, 1990	FEMIDOM (Cl. 5)